Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a population-based cohort

Journal of Acquired Immune Deficiency Syndromes

Volumn 30, Issue 4, 2002, Pages 440-447

  Heath, Katherine V ^a   Hogg, Robert S ^a   Singer, Joel ^a   Chan, Keith J ^a   O'Shaughnessy, Michael V ^a   Montaner, Julio S G ^a  

^a BC Centre for Excellence in HIV/AIDS   (Canada)

Author keywords

Adipose redistribution; Antiretrovirals; Incidence; Lipodystrophy; Protease inhibitors

Indexed keywords

ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; INCIDENCE; LIPOATROPHY; LIPODYSTROPHY; LIPOHYPERTROPHY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RISK ASSESSMENT; STATISTICAL MODEL; SYMPTOMATOLOGY; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0036683037     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-200208010-00010     Document Type: Article

References (37)

1. Improved survival among HIV infected individuals following initiation of antiretroviral therapy
2. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors
3. Studies of body composition and fat distribution in HIV-infected and control subjects
4. Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyperlipidemia, and insulin resistance
5. Buffalo hump and facial wasting in HIV
6. Protease inhibitor-associated hyperglycemia
7. Fat distribution and metabolic changes in patients with HIV infection
8. Visceral abdominal-fat accumulation associated with use of indinavir
9. Development of cervical fat pads following therapy with human immunodeficiency virus type 1 protease inhibitors
10. Clinical and laboratory characteristics of lipodystrophy in a French cohort of HIV-infected patients treated with protease inhibitors
11. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidemia, and diabetes mellitus: A cohort study
12. Marked hypertriglyceridemia associated with ritonavir therapy
13. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients
14. Case report of lipodystrophy observations in patients naive of protease inhibitor treatment, Aquitaine Cohort, 1999
15. Lipodystrophy in 685 HIV-1-treated patients: Influence of antiretroviral treatment and immunovirological response
16. Lipodystrophy-associated morphologic, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database
17. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome
18. Protease inhibitor therapy-associated lipodystrophy, hypertriglyceridaemia and diabetes mellitus
19. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: A 5-year cohort study
20. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection
21. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population
22. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy
23. Lipodystrophy, fat accumulation, and mixed syndrome in protease inhibitor-naive HIV-infected patients
24. Altered fat distribution in HIV-positive men on nucleoside analog reverse transcriptase inhibitor therapy
25. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection
26. Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor
27. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999
28. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: Preliminary results of the LIPOCO study
29. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society- USA Panel
30. The HIV-associated lipodystrophy syndrome: Research, results, yet more questions
31. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: A prospective cohort study
32. Early occurrence of lipodystrophy in HIV-1-infected patients treated during primary infection
33. Localized adipose tissue hypertrophy in patients receiving immunodeficiency virus protease inhibitors
34. Lipodystrophy related to NRT inhibitors in HAART therapy
35. Stavudine versus zidovudine and the development of lipodystrophy
36. Safety, pharmacokinetics and preliminary efficacy of ritonavir, an inhibitor of HIV-1 protease
37. Metabolic effects of protease inhibitor therapy